Imagine dedicating years to battling obesity, only to have the one treatment that finally worked snatched away due to insurance changes. This is the harsh reality for thousands of Massachusetts residents who rely on GLP-1 weight-loss drugs. These medications, including Zepbound, Wegovy, Ozempic, and Mounjaro, have been life-changing for many, offering not just weight loss but significant health improvements. But here's where it gets controversial: major insurers like Blue Cross and Point32Health are dropping coverage for these drugs, leaving patients scrambling to afford them out-of-pocket. And this is the part most people miss—it’s not just about vanity; it’s about managing chronic conditions like high blood pressure, prediabetes, and arthritis. For many, these drugs are a lifeline, not a luxury.
Take the story of Michelle Markert, a 55-year-old interior designer from Newton. After losing 35 pounds on GLP-1s, she now faces a monthly bill of $500, up from just $80. “I don’t take this medicine for the fun of it. I take it because I need it,” she says. Her situation is far from unique. Over 40,000 customers of the state’s two largest insurers have lost coverage this year, and the numbers are expected to rise. The Group Insurance Commission, which covers over 460,000 state employees and their families, recently voted to end GLP-1 coverage for weight loss, and MassHealth may follow suit. In 2024 alone, about 140,400 Massachusetts residents with obesity were prescribed these medications.
So, what happens when insurance coverage ends? Patients are left with tough choices: pay exorbitant out-of-pocket costs, switch to less effective treatments, or risk regaining the weight and facing serious health complications. Dr. Paul Copeland, an endocrinologist at Massachusetts General Hospital, warns of the dangers: “Not only is there a rapid weight gain for most patients, but there is documented re-worsening of comorbidities such as cardiovascular risk factors.”
Insurers point fingers at pharmaceutical giants Eli Lilly and Novo Nordisk, accusing them of charging unsustainable prices. For instance, Zepbound and Wegovy can cost between $900 and $1,300 per month. Blue Cross reported spending $515 million on GLP-1s in 2025, up from $140 million in 2023. To cope with these costs, insurers have laid off employees and restricted coverage. But is this fair to patients who depend on these drugs for their health?
Direct-to-consumer programs like NovoCare and LillyDirect offer alternatives, but prices still range from $149 to $449 per month—far out of reach for many. This has created a two-tier system, where only those who can afford it continue treatment. Robert Atterbury, a 60-year-old audiology office coordinator from Dorchester, lost 20 pounds on GLP-1s but can’t afford the $299 monthly cost without insurance. His weight is already creeping back up, and he fears the return of health issues like heart disease and diabetes.
Susan Elsbree, a public relations executive from Jamaica Plain, is equally frustrated. After losing 35 pounds and improving her blood pressure and arthritis, she’s now paying $199 a month to continue her treatment. “This is about equity as much as anything else,” she says. Her words highlight a growing divide: those who can afford to maintain their health and those who can’t.
Novo Nordisk recently announced plans to cut GLP-1 prices by up to half in 2027, but will this be enough? And what about Eli Lilly, which shows no signs of lowering its prices? Insurers argue that reducing costs is the key to making these drugs accessible, but patients are left in limbo, their health hanging in the balance.
Here’s the burning question: Should access to life-changing medications be determined by who can afford them? Share your thoughts in the comments—do you think insurers, pharmaceutical companies, or policymakers should take responsibility for ensuring these treatments remain available to those who need them most?
